Cargando…
Anchor-based classification and type-C inhibitors for tyrosine kinases
Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468516/ https://www.ncbi.nlm.nih.gov/pubmed/26077136 http://dx.doi.org/10.1038/srep10938 |
_version_ | 1782376517482840064 |
---|---|
author | Hsu, Kai-Cheng Sung, Tzu-Ying Lin, Chih-Ta Chiu, Yi-Yuan Hsu, John T.-A. Hung, Hui-Chen Sun, Chung-Ming Barve, Indrajeet Chen, Wen-Liang Huang, Wen-Chien Huang, Chin-Ting Chen, Chun-Hwa Yang, Jinn-Moon |
author_facet | Hsu, Kai-Cheng Sung, Tzu-Ying Lin, Chih-Ta Chiu, Yi-Yuan Hsu, John T.-A. Hung, Hui-Chen Sun, Chung-Ming Barve, Indrajeet Chen, Wen-Liang Huang, Wen-Chien Huang, Chin-Ting Chen, Chun-Hwa Yang, Jinn-Moon |
author_sort | Hsu, Kai-Cheng |
collection | PubMed |
description | Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in the C-terminal hinge region by docking 4,680 kinase inhibitors into 51 protein kinases, and this finding provides an opportunity for the development of kinase inhibitors with high selectivity and anti-drug resistance. We present an anchor-based classification for tyrosine kinases and discover two type-C inhibitors, namely rosmarinic acid (RA) and EGCG, which occupy two and one specific anchors, respectively, by screening 118,759 natural compounds. Our profiling reveals that RA and EGCG selectively inhibit 3% (EGFR and SYK) and 14% of 64 kinases, respectively. According to the guide of our anchor model, we synthesized three RA derivatives with better potency. These type-C inhibitors are able to maintain activities for drug-resistant EGFR and decrease the invasion ability of breast cancer cells. Our results show that the type-C inhibitors occupying a new pocket are promising for cancer treatments due to their kinase selectivity and anti-drug resistance. |
format | Online Article Text |
id | pubmed-4468516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44685162015-06-18 Anchor-based classification and type-C inhibitors for tyrosine kinases Hsu, Kai-Cheng Sung, Tzu-Ying Lin, Chih-Ta Chiu, Yi-Yuan Hsu, John T.-A. Hung, Hui-Chen Sun, Chung-Ming Barve, Indrajeet Chen, Wen-Liang Huang, Wen-Chien Huang, Chin-Ting Chen, Chun-Hwa Yang, Jinn-Moon Sci Rep Article Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in the C-terminal hinge region by docking 4,680 kinase inhibitors into 51 protein kinases, and this finding provides an opportunity for the development of kinase inhibitors with high selectivity and anti-drug resistance. We present an anchor-based classification for tyrosine kinases and discover two type-C inhibitors, namely rosmarinic acid (RA) and EGCG, which occupy two and one specific anchors, respectively, by screening 118,759 natural compounds. Our profiling reveals that RA and EGCG selectively inhibit 3% (EGFR and SYK) and 14% of 64 kinases, respectively. According to the guide of our anchor model, we synthesized three RA derivatives with better potency. These type-C inhibitors are able to maintain activities for drug-resistant EGFR and decrease the invasion ability of breast cancer cells. Our results show that the type-C inhibitors occupying a new pocket are promising for cancer treatments due to their kinase selectivity and anti-drug resistance. Nature Publishing Group 2015-06-16 /pmc/articles/PMC4468516/ /pubmed/26077136 http://dx.doi.org/10.1038/srep10938 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Hsu, Kai-Cheng Sung, Tzu-Ying Lin, Chih-Ta Chiu, Yi-Yuan Hsu, John T.-A. Hung, Hui-Chen Sun, Chung-Ming Barve, Indrajeet Chen, Wen-Liang Huang, Wen-Chien Huang, Chin-Ting Chen, Chun-Hwa Yang, Jinn-Moon Anchor-based classification and type-C inhibitors for tyrosine kinases |
title | Anchor-based classification and type-C inhibitors for tyrosine kinases |
title_full | Anchor-based classification and type-C inhibitors for tyrosine kinases |
title_fullStr | Anchor-based classification and type-C inhibitors for tyrosine kinases |
title_full_unstemmed | Anchor-based classification and type-C inhibitors for tyrosine kinases |
title_short | Anchor-based classification and type-C inhibitors for tyrosine kinases |
title_sort | anchor-based classification and type-c inhibitors for tyrosine kinases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468516/ https://www.ncbi.nlm.nih.gov/pubmed/26077136 http://dx.doi.org/10.1038/srep10938 |
work_keys_str_mv | AT hsukaicheng anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT sungtzuying anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT linchihta anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT chiuyiyuan anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT hsujohnta anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT hunghuichen anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT sunchungming anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT barveindrajeet anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT chenwenliang anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT huangwenchien anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT huangchinting anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT chenchunhwa anchorbasedclassificationandtypecinhibitorsfortyrosinekinases AT yangjinnmoon anchorbasedclassificationandtypecinhibitorsfortyrosinekinases |